Answers are grounded in this paper and cite their sources.
risankizumab is a humanized IgG monoclonal antibody that binds with high affinity and specificity to the p19 subunit and selectively inhibits IL-23, critical for psoriatic inflammation. In phase-3 trials (UltIMMa-1, UltIMMa-2, and IMMvent) risankizumab demonstrated early and sustained efficacy at 12-week dosing in patients with moderate-to-severe psoriasis.1,2 To date, limited real-life data are available on its effectiveness and safety.
No takes yet. Share an insight, caveat, or question.
Hansel et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: